Caricamento...
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
BACKGROUND: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). METHODS: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic prog...
Salvato in:
| Pubblicato in: | BMC Cancer |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6518639/ https://ncbi.nlm.nih.gov/pubmed/31088401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5678-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|